JP2007513183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513183A5 JP2007513183A5 JP2006542849A JP2006542849A JP2007513183A5 JP 2007513183 A5 JP2007513183 A5 JP 2007513183A5 JP 2006542849 A JP2006542849 A JP 2006542849A JP 2006542849 A JP2006542849 A JP 2006542849A JP 2007513183 A5 JP2007513183 A5 JP 2007513183A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- apoptosis
- condition
- composition according
- modulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010059512 Apoptosis Diseases 0.000 claims 7
- 230000006907 apoptotic process Effects 0.000 claims 7
- 230000000051 modifying Effects 0.000 claims 6
- 102000003945 NF-kappa B Human genes 0.000 claims 4
- 108010057466 NF-kappa B Proteins 0.000 claims 4
- 108010040721 Flagellin Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 230000003078 antioxidant Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 230000001640 apoptogenic Effects 0.000 claims 2
- 244000045947 parasites Species 0.000 claims 2
- 230000003537 radioprotector Effects 0.000 claims 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims 1
- 229960001097 Amifostine Drugs 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 206010073306 Exposure to radiation Diseases 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 102100002692 NFKB1 Human genes 0.000 claims 1
- 101700086102 NFKB1 Proteins 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039447 Salmonellosis Diseases 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000000607 poisoning Effects 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
Claims (19)
- アポトーシスを誘発する状態から哺乳動物を保護するための組成物であって、該組成物は、
NFκBを誘導する因子
を含み、該組成物は、該保護を必要とする哺乳動物に投与するのに適していることを特徴とする、組成物。 - 前記因子がフラジェリンおよびTGFβからなる群より選択される、請求項1に記載の組成物。
- 前記因子が潜在性TGFβである、請求項2に記載の組成物。
- 前記状態が放射線への曝露である、請求項1に記載の組成物。
- 前記組成物が、放射線防護剤と組み合わせて投与するのに適していることを特徴とする、請求項2に記載の組成物。
- 前記放射線防護剤が、抗酸化剤である、請求項5に記載の組成物。
- 前記抗酸化剤が、アミホスチンおよびビタミンEからなる群より選択される、請求項6に記載の組成物。
- 前記放射線防護剤が、サイトカインである、請求項5に記載の組成物。
- 前記サイトカインが、幹細胞因子である、請求項8に記載の組成物。
- 前記状態が、癌処置である、請求項1に記載の組成物。
- 前記状態が、構成的に活性なNF−κB癌である、請求項1に記載の組成物。
- 前記癌処置が、化学療法または放射線療法である、請求項10に記載の組成物。
- 前記組成物が、前記状態の前の投与、前記状態と一緒の投与、または前記状態の後の投与に適していることを特徴とする、請求項1〜12のうちのいずれか1項に記載の組成物。
- 前記状態が、細胞老化、放射線、創傷、中毒、感染および温度ショックからなる群より選択される、請求項1に記載の組成物。
- 請求項2〜14のうちのいずれか1項に記載の組成物であって、前記フラジェリンが、フラジェリンに由来するN末端およびC末端のD1領域およびD2領域を含む、組成物。
- アポトーシスのモジュレーターをスクリーニングするための方法であって、該方法は、
(a)疑わしいモジュレーターを、細胞ベースのアポトーシス系に添加する工程;
(b)コントロールを、細胞ベースのアポトーシス系に別に添加する工程;および
(c)工程(a)におけるアポトーシスのレベルと工程(b)におけるアポトーシスのレベルとを比較する工程;
を包含し、該疑わしいモジュレーターは、哺乳動物寄生体に由来する、方法。 - 請求項16に記載の方法であって、前記アポトーシスのモジュレーターがNF−κBのモジュレーターであり、前記細胞ベースのアポトーシス系が、NF−κBで活性化された発現系であり、前記アポトーシスのレベルが、NF−κBで活性化された発現のレベルである、方法。
- 請求項16に記載の方法であって、前記寄生体は、Salmonella、Mycoplasma、およびChlamydiaからなる群より選択される種である、方法。
- 請求項18に記載の方法によって同定された、モジュレーターおよびそのすべての誘導体。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52646103P | 2003-12-02 | 2003-12-02 | |
US52646003P | 2003-12-02 | 2003-12-02 | |
US52649603P | 2003-12-02 | 2003-12-02 | |
US52666603P | 2003-12-02 | 2003-12-02 | |
US60/526,496 | 2003-12-02 | ||
US60/526,460 | 2003-12-02 | ||
US60/526,666 | 2003-12-02 | ||
US60/526,461 | 2003-12-02 | ||
PCT/US2004/040753 WO2005056042A2 (en) | 2003-12-02 | 2004-12-02 | Methods of protecting against radiation using flagellin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007513183A JP2007513183A (ja) | 2007-05-24 |
JP2007513183A5 true JP2007513183A5 (ja) | 2008-01-17 |
JP4750716B2 JP4750716B2 (ja) | 2011-08-17 |
Family
ID=34682348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006542849A Expired - Fee Related JP4750716B2 (ja) | 2003-12-02 | 2004-12-02 | フラジェリンを使用して放射線から保護する方法 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11235028B2 (ja) |
EP (1) | EP1706133B1 (ja) |
JP (1) | JP4750716B2 (ja) |
KR (1) | KR101287905B1 (ja) |
CN (1) | CN1913915B (ja) |
AT (1) | ATE483467T1 (ja) |
AU (1) | AU2004296828B2 (ja) |
CA (1) | CA2547869C (ja) |
DE (1) | DE602004029500D1 (ja) |
DK (1) | DK1706133T3 (ja) |
EA (1) | EA010291B1 (ja) |
HK (1) | HK1102492A1 (ja) |
IL (1) | IL175974A (ja) |
PL (1) | PL1706133T3 (ja) |
PT (1) | PT1706133E (ja) |
SG (2) | SG176524A1 (ja) |
SI (1) | SI1706133T1 (ja) |
UA (1) | UA83272C2 (ja) |
WO (3) | WO2005057218A2 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006069198A1 (en) | 2004-12-22 | 2006-06-29 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
NZ565063A (en) * | 2005-06-13 | 2011-04-29 | Cleveland Biolabs Inc | Methods of protecting against apoptosis using lipopeptides |
EP2200431B1 (en) | 2007-09-10 | 2016-07-20 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
WO2009102818A1 (en) * | 2008-02-11 | 2009-08-20 | Cleveland Biolabs, Inc. | Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
WO2010014957A1 (en) * | 2008-08-01 | 2010-02-04 | Cleveland Biolabs, Inc. | Methods for treating reperfusion injuries |
KR101254244B1 (ko) * | 2010-11-01 | 2013-04-12 | 한국원자력의학원 | TGF-β1을 유효성분으로 함유하는 방사선 피폭 또는 조사에 의한 세포손상의 예방 또는 치료용 조성물 |
KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
CN102965386A (zh) * | 2011-09-02 | 2013-03-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法 |
US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
KR20150085146A (ko) * | 2014-01-13 | 2015-07-23 | 한국원자력의학원 | 소포체 스트레스 저해제를 포함하는 방사선 방호용 조성물 |
EA035372B1 (ru) | 2014-07-30 | 2020-06-03 | Джиноум Протекшн, Инк. | Флагеллиновые композиции и их применение |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
KR101634380B1 (ko) | 2015-06-23 | 2016-06-28 | 한국생산기술연구원 | Tlr5 아고니스트 단백질의 생산방법 |
JP6945532B2 (ja) * | 2015-12-16 | 2021-10-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 改善された組換え体作製方法 |
CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
JP2021522271A (ja) * | 2018-04-24 | 2021-08-30 | ゲノム プロテクション,インコーポレイテッド | 虚弱および加齢を改善するための方法 |
KR102524577B1 (ko) * | 2019-04-22 | 2023-04-21 | 전남대학교산학협력단 | 플라젤린 융합 단백질 및 이의 용도 |
WO2022086190A1 (ko) * | 2020-10-20 | 2022-04-28 | 주식회사 메디스팬 | 플라젤린 융합 단백질 및 이의 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399494A (en) | 1983-03-04 | 1995-03-21 | The University Of Maryland System | Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom |
US6130082A (en) * | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
US20020009747A1 (en) * | 1997-08-25 | 2002-01-24 | Freda Diane Miller | Methods and reagents for identifying modulators of neuronal apoptosis |
US7300749B2 (en) * | 2000-02-17 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
AU2002216500A1 (en) * | 2000-11-28 | 2002-06-11 | Genesis Research And Development Corporation Limited | Methods for modulating apoptotic cell death |
WO2003028659A2 (en) * | 2001-10-02 | 2003-04-10 | University Of Chicago | Methods and compositions for modulating apoptosis |
US7078165B2 (en) * | 2003-03-27 | 2006-07-18 | Institut Pasteur | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
US7638485B2 (en) | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
WO2006069198A1 (en) | 2004-12-22 | 2006-06-29 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
-
2004
- 2004-12-02 CA CA2547869A patent/CA2547869C/en active Active
- 2004-12-02 EA EA200601079A patent/EA010291B1/ru not_active IP Right Cessation
- 2004-12-02 SG SG2011087681A patent/SG176524A1/en unknown
- 2004-12-02 SG SG200809013-6A patent/SG148215A1/en unknown
- 2004-12-02 DK DK04813124.7T patent/DK1706133T3/da active
- 2004-12-02 AU AU2004296828A patent/AU2004296828B2/en not_active Ceased
- 2004-12-02 EP EP04813124A patent/EP1706133B1/en active Active
- 2004-12-02 UA UAA200607304A patent/UA83272C2/uk unknown
- 2004-12-02 PT PT04813124T patent/PT1706133E/pt unknown
- 2004-12-02 PL PL04813124T patent/PL1706133T3/pl unknown
- 2004-12-02 CN CN2004800412595A patent/CN1913915B/zh active Active
- 2004-12-02 JP JP2006542849A patent/JP4750716B2/ja not_active Expired - Fee Related
- 2004-12-02 WO PCT/US2004/040579 patent/WO2005057218A2/en active Application Filing
- 2004-12-02 WO PCT/US2004/040753 patent/WO2005056042A2/en active Application Filing
- 2004-12-02 WO PCT/US2004/040750 patent/WO2005056055A2/en active Application Filing
- 2004-12-02 DE DE602004029500T patent/DE602004029500D1/de active Active
- 2004-12-02 AT AT04813124T patent/ATE483467T1/de active
- 2004-12-02 SI SI200431577T patent/SI1706133T1/sl unknown
- 2004-12-02 KR KR1020067010934A patent/KR101287905B1/ko active IP Right Grant
-
2006
- 2006-05-28 IL IL175974A patent/IL175974A/en active IP Right Grant
-
2007
- 2007-07-25 HK HK07108097.8A patent/HK1102492A1/xx not_active IP Right Cessation
-
2019
- 2019-07-31 US US16/527,770 patent/US11235028B2/en active Active
-
2021
- 2021-12-21 US US17/557,438 patent/US20220105155A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007513183A5 (ja) | ||
Xu et al. | Melatonin prevents obesity through modulation of gut microbiota in mice | |
Kenney et al. | Heat waves, aging, and human cardiovascular health | |
Awad et al. | Melatonin hormone profile in infertile males | |
Bussmann et al. | Early markers for protective mechanisms during rush venom immunotherapy | |
Yasuda et al. | 5‐HT3 receptor antagonists ameliorate 5‐fluorouracil‐induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells | |
Ma et al. | Casticin prevents DSS induced ulcerative colitis in mice through inhibitions of NF‐κB pathway and ROS signaling | |
Zhan et al. | Activation of Akt/FoxO and inactivation of MEK/ERK pathways contribute to induction of neuroprotection against transient global cerebral ischemia by delayed hypoxic postconditioning in adult rats | |
Iggena et al. | Melatonin restores hippocampal neural precursor cell proliferation and prevents cognitive deficits induced by jet lag simulation in adult mice | |
Xuan et al. | Epigenetic modulation in periodontitis: interaction of adiponectin and JMJD3‐IRF4 axis in macrophages | |
Charles et al. | Polyphenols prevent ageing‐related impairment in skeletal muscle mitochondrial function through decreased reactive oxygen species production | |
BR0211915A (pt) | Execução de aplicação habilitada para teste | |
Alayev et al. | Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation | |
Shao et al. | Neuroinflammation and neuronal autophagic death were suppressed via Rosiglitazone treatment: new evidence on neuroprotection in a rat model of global cerebral ischemia | |
Lahiri et al. | Melatonin protects against experimental reflux esophagitis | |
Mahran et al. | Carvacrol and Thymol Modulate the Cross‐Talk between TNF‐α and IGF‐1 Signaling in Radiotherapy‐Induced Ovarian Failure | |
Shi et al. | LPS pretreatment ameliorates multiple organ injuries and improves survival in a murine model of polymicrobial sepsis | |
Bayrami et al. | Combination of vildagliptin and ischemic postconditioning in diabetic hearts as a working strategy to reduce myocardial reperfusion injury by restoring mitochondrial function and autophagic activity | |
Liu et al. | Effect of Helicobacter pylori infection on Barrett’s esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux | |
Oh et al. | Synergism of Helicobacter pylori infection and stress on the augmentation of gastric mucosal damage and its prevention with α-tocopherol | |
Chao et al. | Calycosin attenuates dextran sulfate sodium (DSS)-induced experimental colitis | |
Peng et al. | Action mechanism of Ginkgo biloba leaf extract intervened by exercise therapy in treatment of benign prostate hyperplasia | |
Fatani et al. | Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis | |
Jindam et al. | Nrf2: a promising trove for diabetic wound healing | |
Yang et al. | RETRACTED ARTICLE: Lycium barbarum polysaccharide prevents cisplatin-induced MLTC-1 cell apoptosis and autophagy via regulating endoplasmic reticulum stress pathway |